ArticleDiscover oncology2026
Single-cell RNA sequencing combined with single-cell genome-wide association study identifies SF3B4 as a hub gene in hepatocellular carcinoma progression.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHigh heterogeneity and poor therapeutic response are major challenges in hepatocellular carcinoma (HCC). This study aimed to identify core hepatocyte subsets and key genes driving HCC progression via a multi-omics approach to inform precise diagnosis and treatment.
methodsWe analyzed public data from GEO (GSE282701), TCGA-LIHC, and IEU-Open-GWAS (bbj-a-158). scRNA-seq, scPagwas, BayesPrism, and WGCNA were used to identify core HCC cell subsets and genes. SF3B4 expression was validated by Western blot and RT-qPCR in HCC tissues and cell lines. Functional impacts on proliferation and migration were assessed using colony formation, Transwell, and wound healing assays in HepG2 and Huh7 cells.
resultsIntegrated scRNA-seq and scPagwas analysis identified PKHD1⁺ hepatocytes as a core HCC subset, showing significantly higher trait relevance scores versus other subtypes and a positive correlation with HCC (P < 0.05). BayesPrism quantification in the TCGA-LIHC cohort confirmed that high abundance of PKHD1⁺ hepatocytes correlated with poor prognosis (P < 0.05), immune microenvironment remodeling (increased CAFs and MDSCs), and distinct somatic mutation profiles (elevated CTNNB1 and reduced TP53 mutation rates). SF3B4 was identified as the key gene associated with this subset via WGCNA and differential expression analysis. SF3B4 was upregulated in HCC tissues and cells, and its knockdown suppressed proliferation and migration in HepG2 and Huh7 cells.
conclusionThe PKHD1⁺ hepatocyte subset and SF3B4 represent key regulators of HCC malignancy, offering novel potential targets for prognostic assessment and targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.